This Phase IB trial is focused on finding the optimal dosage for the formulation of Oramed’s proprietary oral insulin delivery technology. The study utilizes healthy human volunteers in order to determine the final formulation of the oral insulin product. This trial is a continuation of Oramed’s successfully completed Phase IA trials, which were conducted on healthy volunteers.
Nadav Kidron, CEO of Oramed, said: “This phase of the trial, following the successful completion of our Phase IA trials, is a significant milestone for Oramed and for our oral insulin product.”